- Market Capitalization, $K 37,416,108
- Shares Outstanding, K 2,055,830
- Annual Sales, $ 109,766 M
- Annual Income, $ 18,210 M
- 60-Month Beta 1.61
- Price/Sales 1.73
- Price/Cash Flow 2.35
- Price/Book 2.11
|Period||Period Low||Period High||Performance|
| || |
+0.98 (+5.63%)since 10/15/19
| || |
+2.68 (+17.06%)since 08/15/19
| || |
-2.24 (-10.86%)since 11/15/18
An increase in crude transported volume primarily aids Ecopetrol's (EC) Q3 earnings.
Ecopetrol reports that its US subsidiary, Ecopetrol America LLC, has participated in the drilling of the Esox-1 well under a Farmout Agreement with Chevron U.S.A. Inc. The well which resulted in the discovery...
Ecopetrol S.A. (BVC: ECOPETROL, NYSE: EC) reports that, as mentioned in certain media and in searches on the Judiciary website, the Colombian Supreme Court of Justice has handed down a ruling upholding...
Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC) announced today the Ecopetrol Group's financial results for the third quarter and the first nine months of 2019, prepared in accordance with International Financial...
Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC) ("Ecopetrol" or the "Company) announces that on October 29, 2019 after market close, it will release its financial and operating results for the third quarter...
Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC) reports that regulatory approvals were received today in the United States to form the joint venture between Ecopetrol and OXY, announced last July 31 in a press...
-- The Company will hold a 30% interest. Shell will continue as operator with 50%, while Total will retain 20%.
Is Ecopetrol (EC) a great pick from the value investor's perspective right now? Read on to know more.
Tecnoglass, Inc. (NASDAQ: TGLS) ("Tecnoglass" or the "Company"), a leading manufacturer of architectural glass, windows, and associated aluminum products for the global commercial and residential construction...
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.